Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diff...
Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine, 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c‐FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetylase inhibitor family.
Alternative Titles
Full title
Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_96c0fc1b619649b2a99a1e4014506df6
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_96c0fc1b619649b2a99a1e4014506df6
Other Identifiers
ISSN
2001-1326
E-ISSN
2001-1326
DOI
10.1002/ctm2.858
